Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Dassault Systèmes Q3 2026 slides: platform drives 5% growth, guidance raised

Dassault Systèmes Q3 2026 slides: platform drives 5% growth, guidance raised

On October 28, 2026, Dassault Systèmes released its Q3 2026 financial results, outperforming expectations with a 5% growth in revenue on a constant currency basis. The company also raised its full-year guidance, positioning 2026 as a foundation year for its AI-native transformation. CEO Pascal Daloz highlighted strong customer wins across industries and a significant reorganization of its life sciences business following the ArisGlobal acquisition.

Despite the positive outlook, shares fell 2.31% to $24.12, near the stock's 52-week high of $24.98, as investors remained cautious. Revenue reached €1,552 million, with diluted earnings per share increasing by 8% to €0.32. Operating margin expanded by 150 basis points to 31.6%, indicating improved operational efficiency. Software revenue grew 5% year-over-year, with upfront license revenue surging 14% and recurring revenue advancing 3%.

Subscription revenue, now accounting for 50% of total recurring revenue, increased 6%, marking a shift toward predictable revenue streams. The 3DEXPERIENCE platform, highlighted for its success, contributed 44% to eligible software revenue, up from 40% previously. Cloud revenue, representing 27% of year-to-date software revenue, grew 14%.

Annual recurring revenue (ARR) reached €4.505 billion, up 6% year-over-year. Regional performance varied, with Asia leading growth at 12%, driven by China's expansion and aerospace high-tech sectors, while the Americas declined 3%, attributed to difficult year-over-year comparisons. In life sciences, the company announced a transformation led by Dr. Ashwini Zenooz, aimed at creating an AI-native platform for the entire drug development lifecycle.

This strategic shift is supported by the ArisGlobal acquisition, which enables end-to-end integration of various stages in the pharmaceutical and biotech sectors.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →

More in Finance & Markets

More from Wednesday 28 October →